TY - JOUR
T1 - Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T
T2 - A phantom study
AU - Bertolino, Nicola
AU - Marchionni, Chiara
AU - Ghielmetti, Francesco
AU - Burns, Brian
AU - Finocchiaro, Gaetano
AU - Anghileri, Elena
AU - Bruzzone, Maria Grazia
AU - Minati, Ludovico
PY - 2014
Y1 - 2014
N2 - Purpose: We set out to investigate the potential confounding effect of variable concentration of N-acetyl. l-aspartate (NAA) and Glutamate (Glu) on measurement of the brain oncometabolite 2-hydroxyglutarate (2HG) using a standard MRS protocol. This issue may arise due to spectral overlap at clinical magnetic field strengths and thus complicate the usage of 2HG as a putative biomarker of gliomas bearing mutations of the isocitrate dehydrogenase (IDH) 1 and 2 genes. Methods: Spectra from 25 phantoms (50mL falcon test tubes) containing a range of known concentrations of 2HG, NAA and Glu were acquired using a clinical 3T scanner with a quadrature head coil, single-voxel point-resolved spectroscopy sequence with TE=30ms. Metabolite concentrations were estimated by linear combination analysis and a simulated basis set. Results: NAA and Glu concentrations can have a significant confounding effect on 2HG measurements, whereby the negative changes in concentration of these metabolites typically observed in (peri)lesional areas can lead to under-estimation of 2HG concentration with respect to spectra acquired in presence of physiological levels of NAA and Glu. Conclusion: The confounding effect of NAA and Glu concentration changes needs to be considered: in patients, it may mask the presence of 2HG at low concentrations, however it is not expected to lead to false positives. 2HG data acquired using standard short echo-time MRS protocols should be considered with caution.
AB - Purpose: We set out to investigate the potential confounding effect of variable concentration of N-acetyl. l-aspartate (NAA) and Glutamate (Glu) on measurement of the brain oncometabolite 2-hydroxyglutarate (2HG) using a standard MRS protocol. This issue may arise due to spectral overlap at clinical magnetic field strengths and thus complicate the usage of 2HG as a putative biomarker of gliomas bearing mutations of the isocitrate dehydrogenase (IDH) 1 and 2 genes. Methods: Spectra from 25 phantoms (50mL falcon test tubes) containing a range of known concentrations of 2HG, NAA and Glu were acquired using a clinical 3T scanner with a quadrature head coil, single-voxel point-resolved spectroscopy sequence with TE=30ms. Metabolite concentrations were estimated by linear combination analysis and a simulated basis set. Results: NAA and Glu concentrations can have a significant confounding effect on 2HG measurements, whereby the negative changes in concentration of these metabolites typically observed in (peri)lesional areas can lead to under-estimation of 2HG concentration with respect to spectra acquired in presence of physiological levels of NAA and Glu. Conclusion: The confounding effect of NAA and Glu concentration changes needs to be considered: in patients, it may mask the presence of 2HG at low concentrations, however it is not expected to lead to false positives. 2HG data acquired using standard short echo-time MRS protocols should be considered with caution.
KW - 2-Hydroxyglutarate (2HG)
KW - Accuracy
KW - Brain
KW - Glioma
KW - Magnetic resonance spectroscopy (MRS)
UR - http://www.scopus.com/inward/record.url?scp=84906234988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906234988&partnerID=8YFLogxK
U2 - 10.1016/j.ejmp.2014.03.002
DO - 10.1016/j.ejmp.2014.03.002
M3 - Article
C2 - 24685182
AN - SCOPUS:84906234988
SN - 1120-1797
VL - 30
SP - 702
EP - 707
JO - Physica Medica
JF - Physica Medica
IS - 6
ER -